The introduction of the exclusive distribution right of the third generation diphosphonate drug for the treatment of osseous metastasis - Ibandronic Acid Injection (brand name: Bondronat) in mainland China from Roche Group has helped Techpool gain 1% of domestic market.

After the successful cooperation with national big pharma, Techpool has started to negotiate with Japanese pharmaceutical companies Takeda on the introduction of severe disease and cancer related medication.

Techpool is the global leader in urinary protein biopharmaceuticals which specializes in the sales, R&D and production of biopharmaceuticals in critical care. It is expected that Techpool shall have revenue between RMB 2billion to 4billion in 2016 and become the top 5 global bio-pharma companies.